Neuroendocrine tumor targeting: Study of novel gallium‐labeled somatostatin radiopeptides in a rat pancreatic tumor model

Somatostatin analogs labeled with radionuclides are of considerable interest in the diagnosis and therapy of SSTR‐expressing tumors, such as gastroenteropancreatic, small cell lung, breast and frequently nervous system tumors. In view of the favorable physical characteristics of the Ga isotopes 67 Ga and 68 Ga, enabling conventional tumor scintigraphy, PET and possibly internal radiotherapy, we focused on the development of a Ga‐labeled somatostatin analog suitable for targeting SSTR‐expressing tumors. For this purpose, 3 somatostatin analogs, OC, TOC and TATE were conjugated to the metal chelator DOTA and labeled with the radiometals 111 In, 90 Y and 67 Ga. They were then evaluated for their performance in the AR4‐2J pancreatic tumor model by testing SSTR2‐binding affinity, internalization/externalization in isolated cells and biodistribution in tumor‐bearing nude mice. Surprisingly, we found that, compared to 111 In or 90 Y, labeling with 67 Ga considerably improved the biologic performance of the tested somatostatin analogs with respect to SSTR2 affinity and tissue distribution. 67 Ga‐labeled DOTA‐somatostatin analogs were rapidly excreted from nontarget tissues, leading to excellent tumor‐to‐nontarget tissue uptake ratios. Of interest for radiotherapeutic application, [ 67 Ga]DOTATOC was strongly internalized by AR4‐2J cells. Furthermore, our results suggest a link between the radioligand charge and its kidney retention. The excellent tumor selectivity of Ga‐DOTA somatostatin analogs together with the different applications of Ga in nuclear oncology suggests that Ga‐DOTA somatostatin analogs will become an important tool in the management of SSTR‐positive tumors.